4.8 Article

Genetic and Structural Variation in the Gastric Cancer Kinome Revealed through Targeted Deep Sequencing

期刊

CANCER RESEARCH
卷 71, 期 1, 页码 29-39

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-10-1749

关键词

-

类别

资金

  1. A-star
  2. NMRC
  3. Duke-NUS
  4. CSIS

向作者/读者索取更多资源

Genetic alterations in kinases have been linked to multiple human pathologies. To explore the landscape of kinase genetic variation in gastric cancer (GC), we used targeted, paired-end deep sequencing to analyze 532 protein and phosphoinositide kinases in 14 GC cell lines. We identified 10,604 single-nucleotide variants (SNV) in kinase exons including greater than 300 novel nonsynonymous SNVs. Family-wise analysis of the nonsynonymous SNVs revealed a significant enrichment in mitogen-activated protein kinase (MAPK)-related genes (P < 0.01), suggesting a preferential involvement of this kinase family in GC. A potential antioncogenic role for MAP2K4, a gene exhibiting recurrent alterations in 2 lines, was functionally supported by siRNA knockdown and overexpression studies in wild-type and MAP2K4 variant lines. The deep sequencing data also revealed novel, large-scale structural rearrangement events involving kinases including gene fusions involving CDK12 and the ERBB2 receptor tyrosine kinase in MKN7 cells. Integrating SNVs and copy number alterations, we identified Hs746T as a cell line exhibiting both splice-site mutations and genomic amplification of MET, resulting in MET protein overexpression. When applied to primary GCs, we identified somatic mutations in 8 kinases, 4 of which were recurrently altered in both primary tumors and cell lines (MAP3K6, STK31, FER, and CDKL5). These results demonstrate that how targeted deep sequencing approaches can deliver unprecedented multilevel characterization of a medically and pharmacologically relevant gene family. The catalog of kinome genetic variants assembled here may broaden our knowledge on kinases and provide useful information on genetic alterations in GC. Cancer Res; 71(1); 29-39. (C) 2010 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA

Jonathan Poh, Kao Chin Ngeow, Michelle Pek, Kian-Hin Tan, Jing Shan Lim, Hao Chen, Choon Kiat Ong, Jing Quan Lim, Soon Thye Lim, Chwee Ming Lim, Boon Cher Goh, Yukti Choudhury

Summary: Next-generation sequencing of circulating tumor DNA offers a promising approach to cancer diagnostics, providing minimally invasive serial testing and broad genomic coverage through a simple blood draw, maximizing therapeutic benefit for patients.

PLOS ONE (2022)

Article Oncology

Anti-CD40L therapy prevents the formation of precursor lesions to gastric B-cell MALT lymphoma in a mouse model

Le Ying, Phoebe Liu, Zhoujie Ding, Georgie Wray-McCann, Jack Emery, Nina Colon, Lena H. M. Le, Le Son Tran, Ping Xu, Liang Yu, Dana J. Philpott, Yugang Tu, Daryl M. Z. Cheah, Chee L. Cheng, Soon T. Lim, Choon K. Ong, Richard L. Ferrero

Summary: This study established a new mouse model to study gastric MALT lymphoma and found that mice with a myeloid-specific deletion of Nlrc5 develop precursor B-cell lesions to MALT lymphoma after Helicobacter infection in a shorter time. The lesions in these mice have similar histopathological features to the human disease and are accompanied by an immunosuppressive tissue microenvironment. The study also demonstrated that anti-CD40L antibody can prevent gastric B-cell lesions in mice and reduce the number of immune cells in the stomach.

JOURNAL OF PATHOLOGY (2023)

Correction Multidisciplinary Sciences

Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer (Dec, 10.1038/s41467-019-13824-9, 2022)

Lina Sieverling, Chen Hong, Sandra D. Koser, Philip Ginsbach, Kortine Kleinheinz, Barbara Hutter, Delia M. Braun, Isidro Cortes-Ciriano, Ruibin Xi, Rolf Kabbe, Peter J. Park, Roland Eils, Matthias Schlesner, Benedikt Brors, Karsten Rippe, David T. W. Jones, Lars Feuerbach

NATURE COMMUNICATIONS (2022)

Article Oncology

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide

Jinghong Chen, Zhixiang Zuo, Yan Gao, Xiaosai Yao, Peiyong Guan, Yali Wang, Zhimei Li, Zhilong Liu, Jing Han Hong, Peng Deng, Jason Yongsheng Chan, Daryl Ming Zhe Cheah, Jingquan Lim, Kelila Xin Ye Chai, Burton Kuan Hui Chia, Jane Wan Lu Pang, Joanna Koh, Dachuan Huang, Haixia He, Yichen Sun, Lizhen Liu, Shini Liu, Yuhua Huang, Xiaoxiao Wang, Hua You, Sahil Ajit Saraf, Nicholas Francis Grigoropoulos, Xiaoqiu Li, Jinxin Bei, Tiebang Kang, Soon Thye Lim, Bin Tean Teh, Huiqiang Huang, Choon Kiat Ong, Jing Tan

Summary: This study suggests that combination therapy with chidamide and JAK-STAT inhibitors can be a novel targeted therapy in the standard of care for NKTL (Natural killer/T-cell lymphoma).

CLINICAL EPIGENETICS (2023)

Review Immunology

Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma

Daniel Ren Yi Yap, Jing Quan Lim, Dachuan Huang, Choon Kiat Ong, Jason Yongsheng Chan

Summary: Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare subtypes of non-Hodgkin's lymphoma with poor treatment outcomes. Current treatment strategies involve combination chemoimmunotherapy, radiation, and/or stem cell transplant. However, there is a lack of validated biomarkers for personalized therapy, leading to high failure rates and missed treatment opportunities. Recent research advancements have improved our understanding of these diseases, but clinical translation is still hindered. This review summarizes the progress and challenges in predictive biomarker landscape and implications for novel therapeutics development in PTCL and NKTCL.

FRONTIERS IN IMMUNOLOGY (2023)

Article Biochemistry & Molecular Biology

EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer

Jianfeng Chen, Jing Han Hong, Yulin Huang, Shini Liu, Jiaxin Yin, Peng Deng, Yichen Sun, Zhaoliang Yu, Xian Zeng, Rong Xiao, Jason Yongsheng Chan, Peiyong Guan, Yali Wang, Peili Wang, Lizhen Liu, Shijun Wen, Qiang Yu, Choon Kiat Ong, Bin-Tean Teh, Ying Xiong, Jing Tan

Summary: This study reveals that EZH2 plays an oncogenic role in ovarian cancer through noncatalytic activity. Inhibition of EZH2 degradation, rather than its catalytic activity, can effectively block ovarian cancer growth and tumor formation. Furthermore, EZH2 has extensive occupancy at promoters independent of PRC2 and can upregulate IDH2 to promote metabolic rewiring and contribute to ovarian cancer growth.

MOLECULAR CANCER (2023)

Article Biochemistry & Molecular Biology

Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma

Jianbiao Zhou, Sabrina Hui-Min Toh, Tze King Tan, Kalpnaa Balan, Jing Quan Lim, Tuan Zea Tan, Sinan Xiong, Yunlu Jia, Siok-Bian Ng, Yanfen Peng, Anand D. Jeyasekharan, Shuangyi Fan, Soon Thye Lim, Chin-Ann Johnny Ong, Choon Kiat Ong, Takaomi Sanda, Wee-Joo Chng

Summary: This study identified several super-enhancers (SEs) associated with key transcription factor (TF) genes in extranodal natural killer/T-cell lymphoma (NKTL), including a novel SE named TOX2. Overexpression of TOX2 was found to be associated with worse survival in NKTL patients. Modulating the expression of TOX2 affected the proliferation, survival, and colony formation ability of NKTL cells. Furthermore, a downstream effector of TOX2-mediated oncogenesis, PRL-3, was identified and validated.

MOLECULAR CANCER (2023)

Article Oncology

Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma

Michal Marek Hoppe, Patrick Jaynes, Shuangyi Fan, Yanfen Peng, Shruti Sridhar, Phuong Mai Hoang, Clementine Xin Liu, Sanjay De Mel, Limei Poon, Esther Hian Li Chan, Joanne Lee, Choon Kiat Ong, Tiffany Tang, Soon Thye Lim, Chandramouli Nagarajan, Nicholas F. Grigoropoulos, Soo-Yong Tan, Susan Swee-Shan Hue, Sheng-Tsung Change, Shih-Sung Chuange, Shaoying Li, Joseph D. Khoury, Hyungwon Choi, Carl Harris III, Alessia Bottos, Laura J. Gay, Hendrik F. P. Runge, Ilias Moutsopoulos, Irina Mohorianu, Daniel J. Hodson, Pedro Farinha, Anja Mottok, David W. Scott, Jason J. Pitt, Jinmiao Chen, Gayatri Kumar, Kasthuri Kannan, Wee Joo Chug, Yen Lin Chee, Siok-Bia Ng, Claudio Tripodoe, Anand D. Jeyasekharan

Summary: This study demonstrates that combinations of oncogenes in cellular subpopulations within a cancer can influence clinical outcomes. The percentage of cells with a unique combination of MYC, BCL2, and BCL6 predicts survival in diffuse large B-cell lymphoma (DLBCL), and can be derived mathematically from quantitative measurements of the individual oncogenes. Comparative analysis of DLBCL samples and transformed B cells identifies potential regulators of the unfavorable biology associated with this combination. These findings have implications for understanding cancer evolution and therapy resistance.

CANCER DISCOVERY (2023)

Article Biology

Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma

Jui Wan Loh, Jing Yi Lee, Abner Herbert Lim, Peiyong Guan, Boon Yee Lim, Bavani Kannan, Elizabeth Chun Yong Lee, Ning Xin Gu, Tun Kiat Ko, Cedric Chuan-Young Ng, Jeffrey Chun Tatt Lim, Joe Yeong, Jing Quan Lim, Choon Kiat Ong, Bin Tean Teh, Jason Yongsheng Chan

Summary: A genomic and transcriptomic analysis of angiosarcomas, including samples from the head and neck region, revealed recurrent mutations in CSMD3, LRP1B, MUC16, POT1, and TP53 genes. The study also found that UV-positive angiosarcomas have a higher tumor mutation burden than UV-negative cases. Spatial transcriptomics identified the tumor immune landscape of angiosarcomas, providing insights for the implementation of treatment strategies.

COMMUNICATIONS BIOLOGY (2023)

Article Cell Biology

Diagnostic performance and prognostic value of circulating tumor DNA methylation marker in extranodal natural killer/T cell lymphoma

Xiao-Peng Tian, Yu-Chen Zhang, Ning-Jing Lin, Liang Wang, Zhi-Hua Li, Han-Guo Guo, Shu-Yun Ma, Ming-Jie An, Jing Yang, Yu-Heng Hong, Xian-Huo Wang, Hui Zhou, Ya-Jun Li, Hui-Lan Rao, Mei Li, Shao-Xuan Hu, Tong-Yu Lin, Zhi-Ming Li, He Huang, Yang Liang, Zhong-Jun Xia, Yue Lv, Yu-Ying Liu, Zhao-Hui Duan, Qing-Yu Chen, Jin-Ni Wang, Jun Cai, Ying Xie, Choon-Kiat Ong, Fang Liu, Yan-yan Liu, Zheng Yan, Liang Huang, Rong Tao, Wen-Yu Li, Hui-Qiang Huang, Qing-Qing Cai

Summary: By analyzing the methylation profiles of ENKTL plasma samples, we identified ENKTL-specific ctDNA methylation markers and established a diagnostic and prognosis prediction model. The model is based on ctDNA methylation markers with high specificity and sensitivity, closely related to tumor staging and therapeutic response. Furthermore, we developed a prognostic prediction model with excellent performance, surpassing the Ann Arbor staging and PINK risk system.

CELL REPORTS MEDICINE (2023)

Article Medicine, Research & Experimental

Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma

Yali Wang, Wenbo Zhou, Jianfeng Chen, Jinghong Chen, Peng Deng, Huang Chen, Yichen Sun, Zhaoliang Yu, Diwen Pang, Lizhen Liu, Peili Wang, Jing Han Hong, Bin Tean Teh, Huiqiang Huang, Wenyu Li, Zhengfang Yi, Soon Thye Lim, Yihua Chen, Choon Kiat Ong, Mingyao Liu, Jing Tan

Summary: A new and potent STAT3 inhibitor, WB737, has been developed as a potential therapeutic option for NKTL. It selectively inhibits NKTL with STAT3-activating mutations and suppresses both canonical and noncanonical STAT3 signaling. WB737 shows significant antitumor effects with minimal toxicity, providing a promising strategy for treating NKTL patients.

MEDCOMM (2023)

Article Oncology

Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study

Esther Wei Yin Chang, Valerie Shiwen Yang, Shin Yeu Ong, Hilda Xueqi Kang, Boon Yee Lim, Sanjay de Mel, Esther Ka Yan Ng, Michelle Limei Poon, Ya Hwee Tan, Jianbang Chiang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Tiffany Tang, Miriam Tao, Lay Poh Khoo, Chee Leong Cheng, Dachuan Huang, Choon Kiat Ong, Soon Thye Lim, Jason Yongsheng Chan

Summary: In our multicenter study in Asia, we investigated the clinical factors that affect the outcomes of AITL patients and identified a new prognostic index relevant to Asian patients. In our cohort of 174 patients, the median PFS and OS were 1.8 years and 5.6 years, respectively. Age >60, bone marrow involvement, total white cell count >12 x 10(9)/L, and elevated serum lactate dehydrogenase were associated with poorer PFS and OS in multivariate analyses. A prognostic index (AITL-PI) was developed to categorize patients into low, moderate, and high-risk subgroups, with 5-year OS rates of 84.0%, 44.0%, and 28.0% respectively (p < 0.0001). POD24 was found to be a strong prognostic factor (5-year OS 24% vs 89%, p < 0.0001). Exploratory gene expression studies revealed distinct immune cell profiles and cell signaling signatures among the different risk groups.

LEUKEMIA & LYMPHOMA (2023)

Review Oncology

Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations

Jason Yongsheng Chan, Nagavalli Somasundaram, Nicholas Grigoropoulos, Francesca Lim, Michelle Limei Poon, Anand Jeyasekharan, Kheng Wei Yeoh, Daryl Tan, Georg Lenz, Choon Kiat Ong, Soon Thye Lim

Summary: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, consisting of diverse disease entities with unique molecular and clinico-pathological features. Understanding of the molecular landscape of DLBCL has improved, revealing distinct genomic subtypes with implications for targeted therapy. Recent approvals of new treatment modalities in both frontline and relapsed settings have addressed previous clinical trial challenges. However, issues such as drug accessibility, reimbursement policies, treatment sequencing, and preferences present challenges in real-world oncology practice. This review discusses recent advances in DLBCL therapeutics and their implications on healthcare practices in Singapore.

DISCOVER ONCOLOGY (2023)

Article Hematology

Post-Treatment Neutrophil and Lymphocyte Counts Predict Progression-Free Survival Following First-Line Chemotherapy in Hodgkin's Lymphoma

Grace Fangmin Tan, Siting Goh, Esther Wei Yin Chang, Ya Hwee Tan, Jianbang Chiang, Valerie Shiwen Yang, Eileen Yi Ling Poon, Nagavalli Somasundaram, Mohamad Farid Bin Harunal Rashid, Miriam Tao, Soon Thye Lim, Choon Kiat Ong, Jason Yongsheng Chan

Summary: Our study examines the prognostic value of immunologic changes in Hodgkin's lymphoma by investigating post-treatment lymphocyte count (pALC), neutrophil count (pANC), and the neutrophil-lymphocyte ratio (pNLR). We analyzed patients treated for classical Hodgkin's lymphoma and determined the optimal cutoff values for high pANC, low pALC, and high pNLR in predicting progression-free survival.

HEMATOLOGY REPORTS (2023)

Article Genetics & Heredity

mSigHdp: hierarchical Dirichlet process mixture modeling for mutational signature discovery

Mo Liu, Yang Wu, Nanhai Jiang, Arnoud Boot, Steven G. Rozen

Summary: Mutational signatures are characteristic patterns of mutations discovered through analyzing large sets of samples. Most programs use non-negative matrix factorization (NMF), but the hierarchical Dirichlet process (HDP) mixture models approach is less explored. This study introduces mSigHdp, an improved approach using HDP mixture models to discover mutational signatures, which outperforms NMF-based approaches in terms of positive predictive value and true positive rate in benchmark tests.

NAR GENOMICS AND BIOINFORMATICS (2023)

暂无数据